CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme

F. Cianfriglia, A. Pompili, A. Riccio, A. Grassi

Research output: Contribution to journalArticle

Abstract

One hundred and three patients with hemispheric supratentorial glioblastoma multiforme were studied. All patients were operated on and a histologic diagnosis of glioblastoma multiforme was made. Patients were randomly placed in one of three treatment schedules within 3 weeks of surgery: Group A: combined radiation therapy and drug (CCNU) therapy (26 cases); Group B: CCNU given orally every 6-8 weeks (27 cases); Group C: standard radiation therapy alone (50 cases). All patients were periodically controlled by clinical and instrumental (EEG, scan, EMG, CAT) evaluations; laboratory data examinations were also frequently performed. The treatment results have been evaluated according to length of survival, social quality of life, and positive or negative response to chemotherapy. In the authors' opinion the clinical findings are interesting but the statistical results are somewhat negative, especially when the groups of patients are not homogeneous.

Original languageEnglish
Pages (from-to)1289-1299
Number of pages11
JournalCancer
Volume45
Issue number6
Publication statusPublished - 1980

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme'. Together they form a unique fingerprint.

  • Cite this

    Cianfriglia, F., Pompili, A., Riccio, A., & Grassi, A. (1980). CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme. Cancer, 45(6), 1289-1299.